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Abstract Arteriogenesis or collateral growth is able to
compensate for the stenosis of major arteries. Using dif-
ferential display RT-PCR on growing and quiescent
collateral arteries in a rabbit femoral artery ligation model,
we cloned the rabbit full-length cDNA of osteoglycin/
mimecan. Osteoglycin was present in the adventitia of
collateral arteries as a glycosylated protein without keratan
sulfate side chains, mainly produced by smooth muscle
cells (SMCs) and perivascular ﬁbroblasts. Northern blot,
Western blot, and immunohistochemistry conﬁrmed a
collateral artery-speciﬁc downregulation of osteoglycin
from 6 h to 3 weeks after the onset of arteriogenesis.
Treatment of primary SMCs with the arteriogenic protein
ﬁbroblast growth factor-2 (FGF-2) resulted in a similar
reduction of osteoglycin expression as observed in vivo.
Application of the FGF-2 inhibitor polyanethole sulfonic
acid (PAS) blocked the downregulation of osteoglycin and
interfered with arteriogenesis. From our study we conclude
that downregulation of osteoglycin is a fundamental
requirement for proper arteriogenesis.
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Introduction
Diseases of the cardio-vascular system are the main cause
of death in the USA and Europe [1]. Often these problems
arise from the occlusion of a main artery, leading to a
decrease in blood supply in areas distal to the occlusion. If
the stenosis of a large feeding artery proceeds sufﬁciently
slow (e.g., in weeks or months), the human body is able to
compensate for the effects of these occlusions, the most
effective mechanism of which is the growth of collateral
arteries (arteriogenesis) [2]. These collateral arteries
develop from preexisting anastomoses creating a natural
bypass bridging the occluded artery. The main stimulus for
arteriogenesis is shear stress in contrast to angiogenesis
which relies on ischemia [3]. In fact, collateral growth is
not dependent on ischemia [4, 5]. Arteriogenesis is a
complex process, which starts with a structural dilatation
of the collateral artery wall, followed by a well-orches-
trated mechanism of vascular growth. This requires
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eration, cell death, smooth muscle cell (SMC) phenotypic
shift, and vascular matrix remodeling [6]. The whole
process is triggered by various growth factors and cyto-
kines, e.g., monocyte chemoattractant protein (MCP-1) or
ﬁbroblast growth factor-2 (FGF-2). These factors stimulate
arteriogenesis in a rabbit model, leading to a faster com-
pensation of the blood ﬂow deﬁcit caused by the occlusion
of the femoral artery [7, 8]. In addition, genes which
are involved in the regulation of the cytoskeleton or
the extracellular matrix (ECM) or others like Carp
(cardiac ankyrin repeat protein) [9] and urokinase plas-
minogen activator [4] are differentially expressed during
arteriogenesis.
In order to identify additional genes involved in collat-
eral growth, we started a screen for differentially expressed
genes in rabbit collateral arteries after 3 days and 3 weeks
of ligation of the femoral artery using differential display
reverse transcription-polymerase chain reaction (DDRT-
PCR) [10].
One of the genes identiﬁed was the rabbit orthologue
1
of human osteoinductive factor/osteoglycin [11] or mim-
ecan [12]. Osteoglycin belongs to the family of small
leucine-rich proteoglycans, a group of currently 11 pro-
teins, characterized by leucine-rich repeats in their central
domain. These proteins are located in the ECM and are
important for the regulation of the structure of the matrix,
but also in the regulation of cell cycle and growth factor
actions [13–15]. Here, we present an in depth study on
osteoglycin in a rabbit model of arteriogenesis. We cloned
the full-length cDNA of rabbit osteoglycin and investi-
gated its expression on RNA and protein level in growing
collateral arteries, in a time course of 3 weeks starting
with the induction of arteriogenesis by femoral artery
ligation. The distribution of osteoglycin mRNA and pro-
tein was explored by in situ hybridization and
immunohistochemistry, respectively. To deﬁne the modi-
ﬁcation status of the protein, we performed Western blot
analysis on N-glycanase treated osteoglycin. In addition,
we carried out several in vitro studies using factors known
to stimulate either arteriogenesis or SMC proliferation,
aiming to characterize their potential to regulate osteo-
glycin expression. Finally, we used the rabbit femoral
ligation model to test the capacity of one of these factors
(FGF-2) to regulate osteoglycin expression in vivo and to
conﬁrm the relevance of this proteoglycan in the arterio-
genic process.
Material and methods
Animal model
To induce collateral artery growth, we used the femoral
artery ligation model in New Zealand White rabbits as
described before [16]. In brief, rabbits were anesthetized
with a ketamine/xylacine mixture and the right femoral
artery was occluded with two ligatures 1.5 cm apart from
each other. As a control the left femoral artery was sham
operated. Animal care and all experimental procedures
were performed in accordance to the German and National
Institutes of Health animal legislation guidelines and were
approved by the local animal care and use committees.
For gene expression studies on RNA and protein level,
collateral arteries were isolated 3, 6, 12, 24 h, 3, 7 days,
and 3 weeks after occlusion of the femoral artery or after
sham operation. All samples were snap frozen in liquid
nitrogen or embedded in Tissue-teck mounting media
(Sakura Finitek, Heppenheim, Germany) and stored at
-80C until further analyses. Postmortem angiograms of
the whole hind limb were performed as previously
described [16].
Infusion of PAS
The experimental treatment and the surgical procedure
were performed as previously described [17]. In brief, after
ligation of the right femoral artery, rabbits (body weight
3.7 ± 0.5 kg, aged 3–4 months; n = 4) received polya-
nethole sulfonic acid (PAS) (15 mg/kg per day, Peprotech,
Frankfurt, Germany), via an osmotic minipump connected
to the collateral circulation. All animals tolerated the
treatment well. At day 7, rabbits were subjected to angi-
ography, and collateral arteries from the occluded and the
control legs were isolated and snap frozen as described
above.
RNA isolation, DDRT-PCR, and Northern blot
Isolation of total RNA, DDRT-PCR, and Northern blot
were performed according to standard procedures [18–20].
Differentially expressed cDNAs were cloned in pGEM-T
Easy vector (Promega, Mannheim, Germany) or in pCR-
Script Amp SK(?) (Stratagene, La Jolla, USA) and
sequenced. Full-length osteoglycin cDNA was obtained by
50 RACE using a SMART RACE cDNA ampliﬁcation kit
(Clontech, Mountain View, USA). For Northern hybrid-
ization, 15 lg total RNA from growing and quiescent
collateral arteries were separated on a 1% agarose gel
containing 0.66 M formaldehyde and transferred to Nylon
membrane (Duralon UV-membrane, Stratagene, La Jolla,
USA). The blots were hybridized with [32P] dCTP
1 The nucleotide sequence reported in this article has been submitted
to the GenBank Data Bank with accession number AF487889.
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123random-primed labeled cDNA probes (Rediprime II,
Amersham Biosciences, Freiburg, Germany), exposed to
Storage phosphor screens overnight, and scanned using a
Storm 860 PhosphorImager (Amersham Biosciences,
Freiburg, Germany). For normalization, blots were rehy-
bridized with a speciﬁc 18S RNA oligonucleotide as
described previously [4]. Quantiﬁcation of the signals was
done using ImageQuant software (Amersham Biosciences,
Feiburg, Germany). All experiments were repeated three
times independently.
Antibodies and Western blot analyses
Tissue samples from growing and quiescent collateral
arteries were disrupted in extraction buffer (0.1 M Tris–
HCl, 0.01 M EDTA, 0.04 M DTT, 10% SDS, pH 8.0)
using an ultrasonic device (Sonoplus G70, Bandelin, Ber-
lin, Germany) with the following settings: ﬁve times 30 s,
40% power, 50% cycle. Proteins lysates were separated on
a 4–12% Bis-Tris gel (Invitrogen, Karlsruhe, Germany). To
deglycosylate protein samples, 50 lg of protein was
denatured at 100C for 10 min in 19 Denaturing buffer
(NEB, Frankfurt, Germany), in a total volume of 12 ll.
The denatured protein mixture was placed on ice, and 2 ll
109 G7 buffer, 2 ll 10% NP-40, and 2 ll PNGase F
(500 U/ll, NEB, Frankfurt, Germany) were added. The
reaction continued for 2 h at 37C. Deglycosylated proteins
were separated on a 4–12% Bis-Tris gel (Invitrogen,
Karlsruhe, Germany).
Osteoglycin was detected on the blots using a rat poly-
clonal antibody produced by Eurogentec (Double XP
program, Koeln, Germany) after immunization with a
peptide derived from rabbit osteoglycin (amino acids
79–84, VTPAPPKKENDEMPTC). The secondary anti-
body was a peroxidase-conjugated goat anti-rat IgG (Santa
Cruz, Heidelberg, Germany). Immunoreactive bands were
visualized with the ECL system (Amersham Biosciences,
Freiburg, Germany). All experiments were repeated inde-
pendently three times.
In situ hybridization and immunohistochemistry
The analyses of osteoglycin mRNA and protein in the
growing collaterals by in situ hybridization and immuno-
chemistry were done as described recently [21].
Furthermore, when appropriate, in situ hybridization
with osteoglycin RNA probes or immunoperoxidase
staining with the protein was combined with immunoﬂu-
orescence with vascular smooth muscle a-actin antibodies
(Sigma, Munich, Germany; data not shown) or with the
proliferation marker ki67 (Dako, Hamburg, Germany) in
consecutive cryosections [21]. The omission of the ﬁrst
antibody served as negative control.
Immunohistochemistry and photomicrography for osteo-
glycin were performed equally in all the sections, in order
to minimize variability generated by the method. The
intensity of osteoglycin immunostaining was qualitatively
compared between sections, taken at comparable locations,
from quadriceps muscles of six occluded and six sham
operated rabbits.
Cell culture
We used primary cultures of rabbit aortic SMCs, which
were isolated as described previously for porcine aortic
SMCs [22]. Cells were routinely cultured in medium 199
(PAA, Coelbe, Germany) with 20% FCS and splitted 1:4
upon conﬂuence. For stimulation, cells between passages 4
and 6 were serum starved for 3 days. Stimulation was done
with Oncostatin M (OsM, 10 ng/ml), FGF-2 (20 ng/ml),
transforming growth factor-b (TGF-b1, 5 ng/ml), platelet
derived growth factor-AB (PDGF-AB, 10 ng/ml), and
granulocyte-macrophage colony-stimulating factor (GM-
CSF, 10 ng/ml). All factors used were recombinant human
(Cell Concepts, Umkirch, Germany).
To test the inﬂuence of MCP-1 (10 ng/ml, Boehringer,
Mannheim, Germany) on growth factor actions, all stimu-
lations were repeated as co-stimulations with this
chemokine. RNA was isolated from stimulated and co-
stimulated cells after 24, 48, and 72 h, with peqGOLD
RNApure (PEQLAB, Erlangen, Germany). All experi-
ments were repeated three times.
Statistics
Statistical comparisons were performed with ANOVA and
Bonferroni tests. P values \0.05 were regarded as statis-
tical signiﬁcant.
Results
Cloning and characterization of the rabbit osteoglycin
cDNA
Using DDRT-PCR, we identiﬁed 191 differentially
expressed genes, most of which were downregulated at 3d
and 3 weeks. One of these genes showed a strong homol-
ogy (77%) to the bovine osteoinductive factor (accession
no. M37974). We cloned the full-length cDNA of 2.5 kb by
50 RACE and found that the gene represented the rabbit
orthologue of the bovine osteoglycin/mimecan (Fig. 1). A
single open reading frame of 896 bp coded for a protein of
298 amino acids. Conserved amino acid elements included
an N-terminal signal peptide and three consensus sequen-
ces for N-linked glycosylation. Furthermore, the amino
Mol Cell Biochem (2009) 322:15–23 17
123acid sequence showed seven leucine rich repeats; three of
them represented the 21 amino acid S type and four of them
the longer 26 amino acid T type (Fig. 1). The comparison
of the rabbit osteoglycin amino acid sequence to the
human, bovine, and rat ones showed an identity of 88%,
87%, and 83%, respectively (data not shown).
Osteoglycin expression in collateral arteries
Northern blot analyses on rabbit collateral arteries showed
a 3.2 kb mRNA which was downregulated at nearly all
time points studied (Fig. 2). The mRNA level was
decreased to 31% of the control value as early as 6 and
12 h after femoral artery ligation (all values P\0.05,
Fig. 2A). One day after surgery, osteoglycin production
was still 52% of the control value, remaining at low levels
during the entire ﬁrst week of arteriogenesis (3 days, 43%
and 7 days, 42%, of control; P\0.05; Fig. 2B). After
3 weeks, osteoglycin expression started to return to control
levels (86% of control; not signiﬁcant).
Western blot analyses revealed a double band of
approximately 36–40 kDa (Fig. 3A), corresponding to
glycosylated osteoglycin (see below). Changes in the
expression level of the protein during arteriogenesis were
comparable to those at the mRNA level. The protein con-
tent was reduced to 43% of the control value (P\0.001)
after 3 days and to 48% (P\0.001) after 7 days of sur-
gery (Fig. 3A, B). In contrast to RNA, the protein level was
still low 3 weeks after occlusion of the femoral artery (40%
of control value; P\0.01).
Osteoglycin was initially described as a keratan sulfate
proteoglycan. The core protein can be modiﬁed with oli-
gosaccharides at three possible sites for N-glycosylation
present in the osteoglycin sequence (Fig. 1). To test whe-
ther the detected signals of immunoreactive osteoglycin
reﬂected the unmodiﬁed or the glycosylated protein in
collateral arteries, the oligosaccharide side chains were
removed with N-glycanase, resulting in a shift in the size of
the protein of approximately 3 kDa (Fig. 3C), indicating
that osteoglycin is expressed in collateral arteries as a
glycoprotein without keratan sulfate side chains.
Fig. 1 Sequence of rabbit osteoglycin. The rabbit osteoglycin cDNA
consisted of 2,493 bp and contained an open reading frame coding for
a protein of 298aa. The protein starts with a signal peptide of 19
amino acids (underlined). The three consensus sequences for
N-linked glycosylation are printed in red. The leucine-rich repeats
of the S-type are marked in blue, that of the T-type in green
Fig. 2 Osteoglycin mRNA expression at various time points after
occlusion of the femoral artery. A Bar graphs representing Northern
blot results on osteoglycin expression in growing collateral arteries
from 3 h to 3 weeks after femoral artery ligation (for 3–24 h: n =4
for each time point; for 3d to 3w: n = 8 for each time point; control:
n = 8). B Representative Northern blot showing osteoglycin expres-
sion (top) in quiescent (con) and growing collateral arteries at days 3,
7 as well as 3 weeks after femoral artery occlusion. The blot was
rehybridized with an 18S rRNA speciﬁc probe (bottom). Results are
expressed as mean ± SEM (* P\05 versus con; con control)
18 Mol Cell Biochem (2009) 322:15–23
123Localization of osteoglycin mRNA and protein
The sites of osteoglycin production and accumulation in
collateral arteries were investigated in detail by in situ
hybridization (Fig. 4A, C, D) and immunohistochemistry
(Fig. 4B, E, F), respectively. In collateral arteries, osteo-
glycin mRNA was mainly expressed by SMCs of the media
and cells of the adventitia (Fig. 4C, D). In perivascular
areas, signals were prominent in the ﬁbroblasts of the fascia
that envelops the skeletal muscles. Localization of osteo-
glycin protein was analyzed using the same antibody as for
Western blot (Fig. 4E). The protein was accumulated in the
ECM, with the strongest signals present in the adventitia of
the arteries and the external fascia of the quadriceps mus-
cles. Moderate signals were detected in the matrix
surrounding individual muscle ﬁbers. After 7 days of col-
lateral artery growth, the amount of osteoglycin protein
was clearly diminished in the adventitia of growing col-
lateral arteries (Fig. 4F). These were distinguishable from
neighboring quiescent arteries by the high percentage of
proliferating SMCs in the media (Fig. 4G). Only growing
collateral arteries from ligated animals showed a reduction
of osteoglycin signals in the adventitia, whereas quiescent
arteries from the same individuals, and from sham oper-
ated animals, as well as the muscle fascia of every
specimen showed a constant intensity of staining (compare
Fig. 4E, F).
Factors inﬂuencing osteoglycin expression in vitro
Primary rabbit aortic SMCs were used to investigate the
inﬂuence of growth factors on the expression of osteogly-
cin (Fig. 5). While most factors used showed no or only a
negligible effect Oncostatin M led to a signiﬁcant reduction
of osteoglycin mRNA to 40% of the control value after
24 h of stimulation, 31% after 48 h (P\0.05), and 27%
after 72 h (P\0.05). FGF-2 showed a comparable but
biphasic effect, with a downregulation to 36% of control
value after 24 h (P\0.05), expression levels of 80% after
48 h, dropping again to 40% after 72 h. TGF-b1 had only a
short, limited effect after 48 h of stimulation, similar to
PDGF-AB, with a downregulation to 60% and 63% of the
control value, respectively. GM-CSF or MCP-1 alone
showed no substantial effect.
MCP-1 is a well-known stimulator of arteriogenesis
when used either isolated or in combination with other
factors like GM-CSF. Co-stimulation of TGF-b1 with
MCP-1 caused a deeper effect on osteoglycin downregu-
lation (24 h: 89%, 48 h: 40%, 72 h: 29%) than single TGF-
b1 stimulation (Fig. 5). Co-stimulations using GM-CSF
and MCP-1 or GM-CSF, TGF-b1, and MCP-1 also showed
prominent but non-signiﬁcant reductions when compared
to single stimulations.
FGF-2 as a modulator of osteoglycin expression in vivo
As shown above, FGF-2, a key factor for arteriogenesis,
induced a pattern of osteoglycin downregulation in SMCs
similar to the pattern observed in vivo. Thus, we decided to
investigate whether FGF-2 plays a role in the regulation of
osteoglycin expression in vivo. Surgical occlusion of the
femoral artery was accompanied with continuous systemic
infusion of the FGF-2 inhibitor PAS during 7 days. Post-
mortem angiograms of PAS treated animals showed a
strong reduction in collateral growth after femoral ligation
when compared to untreated rabbits (Fig. 6A) who had big
collateral arteries with a corkscrew-like course (Fig. 6C).
In contrast, PAS treated rabbits showed small collateral
arteries after femoral surgery, with no corkscrew formation
(Fig. 6B).
In contrast to untreated rabbits (Fig. 2), PAS treated
specimens had no signiﬁcant change of osteoglycin mRNA
expression after 7 days of femoral artery ligation (Fig. 6D).
Fig. 3 Western blot analyses of osteoglycin. A Representative
Western blot showing the level of osteoglycin protein in growing
collateral arteries at days 3, 7 and 3 weeks after femoral artery
occlusion as well as in control vessels. B Quantiﬁcation of the
Western blot analyses. n = 7 for control and for d3, n = 6 for d7, and
n = 5 for 3 weeks. Results are expressed as mean ± SEM (* P\05
versus con). C Protein preparations before (-) and after (?)
deglycosylation (n = 4 for each time point). Ponceau S staining
was used in all Western blots to demonstrate equal loading of the
protein samples. (M Cruz marker molecular weight standard, con
control, 3d 3 days after occlusion, 7d 7 days after occlusion, 3w
3 weeks after occlusion)
Mol Cell Biochem (2009) 322:15–23 19
123Fig. 4 Localization of
osteoglycin mRNA (A, C, D),
protein (B, E, F), and the
proliferation marker ki-67 (G)
in collateral arteries and
surrounding tissue. A, C, D
In situ hybridization. A The
hybridization with the sense
probe was used as a negative
control. C, D Positive signals
for osteoglycin were detected in
the SMCs of the collateral
media (arrows) and in
ﬁbroblasts (arrowheads). B, E,
F Immunohistochemistry. B
Negative control for
immunoperoxidase reaction. E
Quiescent collateral arteries
showed a thin media and
continuous internal elastic
lamina (arrow). Note the
prominent staining for
osteoglycin in the adventitia
(black arrowheads). F, G
(consecutive sections): After
7 days of femoral artery
occlusion growing collateral
arteries show fragmented elastic
lamina (arrows in F), prominent
neointima formation (NI in F),
and SMC proliferation (arrows
in G; ki67 staining). Note the
strong reduction of osteoglycin
protein in the adventitia of
growing collateral arteries
(compare black arrowheads in
E and F), whereas in the fascia
of the muscle the signal
intensity remains the same (red
arrowheads)
Fig. 5 Stimulation of SMCs
with distinct cytokines and
growth factors. Bar graphs
representing Northern blot
results on osteoglycin
expression in primary rabbit
SMCs after 24, 48, and 72 h of
stimulation with distinct growth
factors and cytokines. The
factors and concentrations used
are indicated in the ‘‘Material
and Methods’’ section. Results
are expressed as mean ± SEM
(* P\0.05 versus con; con
control, OsM Oncostatin M).
All experiments were performed
in triplicate
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123Thus, PAS treatment abolished osteoglycin downregulation
in collateral arteries induced by femoral ligation.
Discussion
Our study deﬁnes rabbit osteoglycin, a protein of 298
amino acids and a prototype member of the family of small
leucine-rich proteins (SLRP; for an overview see [14]) as a
critical component of arteriogenesis. Northern blot results
showed a single band of 3.2 kb for rabbit osteoglycin
mRNA, which is in agreement with the published mRNA
size for rat [23], therefore excluding differential splicing or
alternative polyadenylation. The mRNA is translated in a
glycosylated protein without keratan sulfate side chains of
36–40 kDa ﬁtting with the theoretical mass (including the
signal peptide) of 34 kDa [23].
The comparative study of osteoglycin expression in
collateral arteries of rabbits subjected to femoral artery
occlusion indicated a clear downregulation during the
entire period under investigation. Localization of osteo-
glycin mRNA and protein in skeletal muscles and vessels
corresponded to that shown in previous studies [21]. One
week after induction of arteriogenesis, osteoglycin protein
was clearly diminished in the adventitia of growing col-
lateral arteries, whereas the surrounding muscle fascia and
quiescent vessels were unaffected. These data also illus-
trate the speciﬁcity of osteoglycin function in the process,
as changes in the amount of the protein were restricted to
growing collateral arteries, whereas osteoglycin amount in
the skeletal muscle matrix did not change.
Our results strongly support previous reports showing
that osteoglycin expression is linked to SMC proliferation
[23] because osteoglycin downregulation during arterio-
genesis coincides with the proliferation phase of SMCs. In
the rabbit hind limb model, proliferation starts 24 h after
femoral artery occlusion, peaks between days 2 and 3, and
gradually decreases until day 21 [24]. Moreover, down-
regulation starts even before mitosis is detected (6 and 12 h
after surgery), suggesting that osteoglycin may be involved
in SMC activation.
Fig. 6 Application of PAS. Postmortem angiograms of rabbit hind
limbs. A After 1 week of infusion of PAS without ligation of the
femoral artery. B After 1 week of femoral artery ligation with
concomitant infusion of PAS. C After 1 week of femoral artery
ligation without infusion of PAS. Upon femoral artery ligation, only
rabbits not treated with PAS (C) showed collateral arteries with
corkscrew formation (arrows), a typical sign for growing collaterals.
D Bar graphs representing Northern blot results on osteoglycin
expression after 1 week of infusion of PAS in resting collateral
arteries (con ? PAS) and in growing collateral arteries 7 days after
ligation of the femoral artery (7d occ ? PAS; n = 4). Results are
expressed as mean ± SEM. No statistical difference was found
c
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123We found evidence that application of FGF-2, a potent
mitogen for SMCs and ﬁbroblasts and a critical element in
arteriogenesis [17], to SMCs in vitro closely mimicked the
downregulation of osteoglycin observed during the ﬁrst
3 days of arteriogenesis in vivo, similar to the one previ-
ously observed in bovine keratocytes [25] and human
SMCs [23].
In addition, infusion of PAS, a nontoxic sulfonic acid
polymer described to block the action of FGF-2 via
complex formation [26] and strongly interfering with
arteriogenesis in vivo [17], completely inhibited the
downregulation of osteoglycin. This demonstrates that
FGF-2 is either directly or indirectly involved in regulating
the expression of osteoglycin during the process of arte-
riogenesis in vivo, probably via the high-afﬁnity receptor
FGFR-1 which is expressed by SMCs of the collateral wall,
whereas FGF-2 is mostly secreted by recruited macro-
phages [17]. Macrophage invasion and activation in the
adventitia of collateral arteries by secreted cytokines like
MCP-1 are critical events during arteriogenesis [27–29].
Interestingly, in our SMC cultures, MCP-1 co-stimulation
enhanced the capacity of most factors tested to down-
regulate osteoglycin. Furthermore, Oncostatin M, another
macrophage-secreted cytokine with a known mitogenic
effect on SMCs [30, 31], induced a signiﬁcant downregu-
lation of osteoglycin at every time point studied. These
data indicate that factors other than FGF-2 may inﬂuence
osteoglycin expression during collateral growth and sup-
port the hypothesis that osteoglycin downregulation is a
necessary mechanism for arteriogenesis progression.
The results of the present study point to a function of
osteoglycin as a negative regulator of the mitotic activity in
the wall of collateral arteries. However, the main function
of osteoglycin as with other SLRPs may be the regulation
of collagen ﬁbrillogenesis in the ECM [14, 32]. Osteo-
glycin knockout mice show reduced tensile strength of the
skin, caused by alterations in the diameters of collagen
ﬁbrils, thereby supporting a role for this proteoglycan in
determining elasticity and tensile strength [21, 32]. During
rabbit peripheral arteriogenesis, collateral artery remodel-
ing leads to a ﬁnal increase in size of 10-fold the original
vessel diameter [7]. It is reasonable to propose that os-
teoglycin downregulation may inﬂuence the structure of
the collagen matrix during the remodeling phase of arte-
riogenesis, allowing the structural dilatation of collateral
arteries. New studies with osteoglycin knockout mouse
models may help in understanding how this glycoprotein
inﬂuences the mechanical properties of the vascular wall
during vascular disease and adaptative growth.
Finally, studies have shown that osteoglycin binds bone
morphogenetic proteins (BMPs), members of the TGF-b
superfamily, thereby regulating their bioavailability and
action [33]. Additional studies are required to address the
possible involvement of BMPs in arteriogenesis and their
regulation by osteoglycin.
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